<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="50364">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02024529</url>
  </required_header>
  <id_info>
    <org_study_id>AP-004-A</org_study_id>
    <nct_id>NCT02024529</nct_id>
  </id_info>
  <brief_title>Randomized, Controlled Study to Evaluate Efficacy and Safety of Intra-articular Ampion for Osteoarthritis Pain in Knee</brief_title>
  <official_title>A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of a Single Intra-articular Injection of AmpionTM (&lt;5 Kilodalton Ultrafiltrate of 5% Human Serum Albumin) in Adults With Pain Due to Osteoarthritis (OA) of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ampio Pharmaceuticals. Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ampio Pharmaceuticals. Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled, double-blind study in which 500 patients with
      osteoarthritis (OA) knee pain will be randomized to Ampion or placebo and followed for 20
      weeks. The clinical effects of treatment on OA pain will be evaluated during clinic visits
      at 6, 12, and 20 weeks using WOMACÂ® osteoarthritis Index and the Patient's Global Assessment
      of disease severity (PGA). Safety will be assessed by recording adverse events, concomitant
      medications, physical examination, vital signs and clinical laboratory tests.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improvement on WOMAC A Pain SubScore</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Ampion &lt; 5 kDa ultrafiltrate of 5% HSA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mL Intra-articular injection of Ampion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 mL placebo intra-articular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ampion</intervention_name>
    <description>kDa ultrafiltrate of 5% human serum albumin</description>
    <arm_group_label>Ampion &lt; 5 kDa ultrafiltrate of 5% HSA</arm_group_label>
    <arm_group_label>Placebo solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis and radiological evidence of symptomatic osteoarthritis of the
             knee

          -  Moderate to severe pain

        Exclusion Criteria:

          -  Other conditions in the knee, e.g., crystal arthropathies, septic necrosis, joint
             replacement, major injury within 12 months prior to screening, tense effusions

          -  Requires ongoing treatment with intra-articular pain medications or systemic
             corticosteroids
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vaughan Clift, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ampio Pharmaceuticals. Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Holli Loose, MSc</last_name>
    <phone>720-437-6528</phone>
    <email>hloose@ampiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Quang Vo, MD</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Cook</last_name>
      <phone>714-269-6161</phone>
      <email>mcook@dreamteamclinic.com</email>
    </contact>
    <investigator>
      <last_name>Quang Vo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 10, 2014</lastchanged_date>
  <firstreceived_date>December 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
